Syneron Medical Ltd. (NASDAQ:ELOS) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Thursday.

Separately, Maxim Group downgraded Syneron Medical from a “buy” rating to a “hold” rating and decreased their target price for the stock from $12.00 to $11.00 in a research report on Friday, May 12th. One analyst has rated the stock with a sell rating, three have issued a hold rating and one has given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $9.95.

Shares of Syneron Medical (NASDAQ ELOS) traded down 0.46% during mid-day trading on Thursday, hitting $10.90. The company’s stock had a trading volume of 325,175 shares. Syneron Medical has a 12-month low of $6.18 and a 12-month high of $11.43. The company’s market cap is $380.39 million. The stock has a 50-day moving average of $10.90 and a 200-day moving average of $10.14.

COPYRIGHT VIOLATION NOTICE: “Syneron Medical Ltd. (NASDAQ:ELOS) Downgraded by BidaskClub” was posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/07/06/syneron-medical-ltd-nasdaqelos-downgraded-by-bidaskclub.html.

Institutional investors have recently added to or reduced their stakes in the stock. Citadel Advisors LLC raised its position in Syneron Medical by 2.1% in the first quarter. Citadel Advisors LLC now owns 11,835 shares of the medical equipment provider’s stock valued at $125,000 after buying an additional 243 shares during the last quarter. GSA Capital Partners LLP increased its stake in Syneron Medical by 7.9% in the fourth quarter. GSA Capital Partners LLP now owns 22,552 shares of the medical equipment provider’s stock worth $189,000 after buying an additional 1,654 shares during the period. Campbell & CO Investment Adviser LLC increased its stake in Syneron Medical by 28.6% in the first quarter. Campbell & CO Investment Adviser LLC now owns 22,781 shares of the medical equipment provider’s stock worth $240,000 after buying an additional 5,065 shares during the period. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its stake in Syneron Medical by 18.0% in the first quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 36,879 shares of the medical equipment provider’s stock worth $389,000 after buying an additional 5,632 shares during the period. Finally, PEAK6 Investments L.P. purchased a new stake in Syneron Medical during the first quarter worth about $111,000. Hedge funds and other institutional investors own 69.17% of the company’s stock.

Syneron Medical Company Profile

Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company’s aesthetic medical products are based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments.

Receive News & Ratings for Syneron Medical Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneron Medical Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.